Investors in Strata Critical Medical, Inc. (NASDAQ:SRTA) had a good week, as its shares rose 6.4% to close at US$5.34 following the release of its first-quarter results. Strata Critical Medical beat expectations by 5.8% with revenues of US$67m. It also surprised on the earnings front, with an unexpected statutory profit of US$0.03 per share a nice improvement on the losses that the analysts forecast. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

Taking into account the latest results, the consensus forecast from Strata Critical Medical's four analysts is for revenues of US$270.0m in 2026. This reflects a meaningful 18% improvement in revenue compared to the last 12 months. Per-share statutory losses are expected to explode, reaching US$0.07 per share. Before this earnings report, the analysts had been forecasting revenues of US$269.2m and earnings per share (EPS) of US$0.08 in 2026. While the analysts have made no real change to their revenue estimates, we can see that the consensus is now modelling a loss next year - a clear dip in sentiment compared to the previous outlook of a profit.

The consensus price target held steady at US$8.88, seemingly implying that the higher forecast losses are not expected to have a long term impact on the company's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Strata Critical Medical, with the most bullish analyst valuing it at US$11.50 and the most bearish at US$8.00 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We can infer from the latest estimates that forecasts expect a continuation of Strata Critical Medical'shistorical trends, as the 25% annualised revenue growth to the end of 2026 is roughly in line with the 26% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 4.8% annually. So it's pretty clear that Strata Critical Medical is forecast to grow substantially faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts are expecting Strata Critical Medical to become unprofitable next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Strata Critical Medical. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Strata Critical Medical going out to 2028, and you can see them free on our platform here..

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.